A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Not Applicable
- Conditions
- ewly Diagnosed Breast CancerSkin DiseasesBreast NeoplasmsBreast DiseasesSkin and Connective Tissue Diseases
- Registration Number
- RPCEC00000329
- Lead Sponsor
- Roche Servicios S.A.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Histological confirmed newly diagnosed stage I to IV (recurrent or de novo) breast cancer no more than 12 months prior to site activation, although they can have received anti-cancer treatment during that time
Exclusion Criteria
1. Patients not receiving treatment for breast cancer with national approved drugs according to standard of care and in line with the current summary of product characteristics (SPC) /local labeling
2. Patients not receiving the Roche studied medicinal product, but a biosimilar
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method